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http://dxObjective:Myocardial damage occurs after valve surgery, but its prognostic implication has not been evaluated.
The aim of the present study was to assess the influence of myocardial damage on mortality and morbidity in
patients undergoing aortic surgery (AVS) and mitral valve surgery (MVS).
Methods: In a prospective multicenter study from the cardiac surgery registry of the Puglia region, cardiac
troponin I (cTnI) was measured immediately after and the morning after the intervention in consecutive patients
undergoing AVS or MVS. The percentile ranks of the cTnI peak values within each center were analyzed.
Results: Of 965 patients (age, 67  12 years; 45.5% women), 579 had undergone AVS and 386 MVS. cTnI
release was significantly greater in the MVS group than in the AVS group and in the nonsurvivors than in the
survivors in both groups. The cTnI cutoff with the greatest sensitivity and specificity (60th percentile for
AVS and 91st for MVS) in predicting hospital mortality (2.6%) was also associated with a greater rate of
postoperative complications and mortality within 3 months postoperatively (multivariate hazard ratio, 3.38;
P¼ .005). Compared with the reference model, which included the multivariate predictors of hospital mortality
(active endocarditis, New York Heart Association class III-IV, left ventricular ejection fraction  30%, and
cardiopulmonary bypass duration), the addition of cTnI greater than the cutoffs showed significant improvement
in model performance (likelihood ratio test, P ¼ .009; net reclassification improvement, 0.751; P< .001;
integrated discrimination improvement, 0.048; P ¼ .002; c-index 0.832 vs 0.838).
Conclusions: An elevated postoperative cTnI level was an independent risk factor for mortality and
morbidity. Measurement of the cTnI level improved the risk reclassification of patients undergoing AVS or
MVS. (J Thorac Cardiovasc Surg 2014;148:2373-9)See related commentary on page 2380.Supplemental material is available online.Cardiac surgery is invariably associated with a certain
degree of myocardial damage. Although myocardial
protection is accomplished through different types ofhe Division of Cardiac Surgery,a Department of Emergency and Organ
plant, University of Bari ‘‘Aldo Moro,’’ Bari, Italy; Health Regional Agency
gliab (AReS Puglia), Bari, Italy; Division of Cardiac Surgery,c Villa Bianca
c, Bari, Italy; Division of Cardiac Surgery,d Villa Verde Clinic, Taranto, Italy;
ion of Cardiac Surgery,e Santa Maria Hospital, Bari, Italy; and Division of
ac Surgery,f Vito Fazzi Hospital, Lecce, Italy.
ures: Authors have nothing to disclose with regard to commercial support.
d for publication Aug 20, 2013; revisions received Sept 30, 2013; accepted for
cation Oct 26, 2013; available ahead of print Dec 2, 2013.
for reprints: Domenico Paparella, MD, Division of Cardiac Surgery,
rtment of Emergency and Organ Transplant, University of Bari
o Moro,’’ Piazza Giulio Cesare, Bari 11-70100, Italy (E-mail: domenico.
ella@uniba.it).
23/$36.00
ht  2014 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2013.10.061
The Journal of Thoracic and Car
P
Mcardioplegic solutions during cardiac arrest, the markers of
myocardial necrosis will be elevated after surgery compared
with the preoperative values. The mechanisms leading to
myocardial damage after cardiac operations are multifacto-
rial and also depend on the type of surgery each patient has
undergone. Most of the studies performed to date on this
subject have focused on patients undergoing coronary artery
bypass grafting (CABG),1-3 with cardiac troponin I (cTnI)
the most reliable marker to detect myocardial damage.
These studies have invariably demonstrated that greater
postoperative cTnI levels are associated with increased
short- andmid-termmortality and a greater rate of postoper-
ative complications after CABG surgery. However, the
extent of myocardial damage differs according to the type
of operation: mitral valve surgery (MVS) provokes greater
cTnI postoperative values than aortic valve surgery (AVS)
and CABG.4 The causes of myocardial damage will also
differ according to the type of surgery. In CABG, coronary
disease extension, recent myocardial infarction, incomplete
revascularization, and early graft failure are possible causes.
In valve surgery heart manipulation and incision, an iatro-
genic coronary lesion and the efficacy of cardioplegia
administration can lead to different degrees of cellular ne-
crosis. From these observations, the extent and prognosticdiovascular Surgery c Volume 148, Number 5 2373
Abbreviations and Acronyms
AVS ¼ aortic valve surgery
CABG ¼ coronary artery bypass grafting
cTnI ¼ cardiac troponin I
MVS ¼ mitral valve surgery
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Mimplication of myocardial damage cannot be generalized;
they should be assessed for each type of procedure. Few
studies have considered myocardial damage after valve sur-
gery,5,6 and its prognostic implications have not been clearly
described. Therefore, the present study aimed to outline the
pattern of myocardial damage in patients undergoing MVS
or AVS without coronary stenosis and to assess its
influence on short- and mid-term mortality and morbidity.
METHODS
Study Population
This was a prospective cohort study in which consecutive adult patients
who had undergone isolated AVS orMVS in the Puglia region from January
1, 2011 to June 30, 2013 were considered. Pre-, intra-, and postoperative in-
formationwere gathered prospectively from the Puglia Regional Adult Car-
diac Surgery Registry, which includes the 7 adult cardiac surgery centers in
Puglia: University of Bari–Policlinico Hospital (coordinating center), An-
thea Hospital (Bari, Italy), Santa Maria Hospital (Bari), Villa Bianca Hos-
pital (Bari), Villa Verde Hospital (Taranto, Italy), Vito Fazzi Hospital
(Lecce, Italy), and Citta di Lecce Hospital (Lecce). Health regional agency
personnel guaranteed the data accuracy and performed the quality control
procedures. All cases performed in each center were checked by operating
roomdocuments to ensure that all patientswho had undergone heart surgery
had been included in the registry. ‘‘Cleaning’’ consisted of minimizing the
amount ofmissing data through interactionswith the hospitals, and auditing
consisted of inspection of the data in the hospital medical records. Hospital
mortality risk prediction was performed for each patient using the Euro-
SCORE II model.7 The postoperative cTnI values were included in the
data set with the specific aim of conducting prospective studies on myocar-
dial damage during cardiac surgery. Of the 7 cardiac surgery units in the re-
gion, 2 were excluded from the analysis because of systematic missing
values for the postoperative myocardial injury biomarkers. The primary
outcomewas hospitalmortality, defined as death occurring at any point after
surgery during the hospital period in which the operation had been per-
formed. The secondary endpoints were the incidence of postoperative com-
plications and mid-term mortality, evaluated as death occurring within 3
months after surgery. Deaths occurring after hospital discharge for patients
resident in Puglia who had undergone surgery before December 2012 were
identified by a link to the regional health information system. The studywas
conducted in accordancewith the Declaration of Helsinki. The institutional
review board policy determined that the research did not require informed
consent.
cTnI Analysis
Blood samples for the determination of the cTnI level were collected at
intensive care unit acceptance and serially thereafter at 7 AM every day of
the intensive care unit stay. The assays included Troponin I STAT
(Roche Diagnostics, Basel, Switzerland), AxSYM Troponin-I (Abbott
Diagnostics, Abbot Park, Ill), and Dimension EXL (Siemens Healthcare
Diagnostics, Malvern, Pa); for 2 centers, the assay used was Dimension
RxL (Siemens Healthcare Diagnostics). The cTnI threshold among the
centers for the diagnosis of myocardial necrosis ranged from 0.056 to
0.40 ng/mL.2374 The Journal of Thoracic and Cardiovascular SurStatistical Analysis
The categorical variables are expressed as percentages and continuous
variables as the mean  standard deviation or median and interquartile
range. Univariate logistic regression analyses were used to assess the
association of baseline variables with the primary outcome. Odds ratios
(OR) are given with the 95% confidence intervals (CIs). The baseline
characteristics associated with mortality on univariate analyses with
P < .05 were retained for possible inclusion in the final model. To
avoid multicollinearity, the redundant variables were removed from the
multivariate logistic regression models, keeping the variable with the
stronger individual effect size. Because the absolute concentrations of
cTnI and the 99th percentile concentrations are currently not comparable
among manufacturers,8-10 the postoperative cTnI peak values were
transformed into percentile ranks for each patient within each center.
Using ranking removed the differences in the assay used without
removing the relative differences among the patients within each clinic.
For each clinic, the distribution varied uniformly from 0 to 100.
A greater cTnI release from each center had a percentile rank close to
100, and a lower release had a percentile rank close to 0. The ranked
data of the centers were combined for the global analysis, and the groups
were compared using the Wilcoxon rank sum test. Multivariate
regression analysis was applied to evaluate the associations between the
operative variables and the percentile ranked cTnI peak values. Receiver
operating characteristics curves were constructed, and the optimal cutoff
points were obtained according to the greatest sum of sensitivity and
specificity. To address the question whether the cTnI level has
incremental prognostic utility, we, first, developed a predictive model
incorporating the clinical variables only (the reference model). Next, we
added cTnI to the reference model. Models with and without cTnI were
compared using a likelihood ratio test. Discrimination was assessed
using the c-statistic,11 and the Akaike information criterion was
calculated.12 The goodness-of-fit for the logistic model was evaluated using
the Nagelkerke likelihood ratio-based R2 measure. The effect of adding
cTnI to the reference model on risk classification was evaluated using
the category-free net reclassification improvement and the integrated
discrimination improvement.13,14 The Cox proportional hazards model
was used to assess the associations of variables with mid-term mortality
during the first 3 months after surgery. The hazard ratios are given
with their 95% CIs. The event-free curves were determined using
Kaplan-Meier analyses stratified by the cTnI cutoff level, and the
comparison was made using the log-rank test. The postoperative
complications were compared using the c2 test. The analyses were made
using STATA software, version 12 (StataCorp, College Station, Tex).
RESULTS
Of 1006 isolated AVS or MVS performed in the 5
participating centers, 965 (95.9%) were included in the
analysis, and 41 (4.1%) were excluded (37 because of
missing postoperative cTnI values and 4 because the patient
died in the operating room). AVS included 5 repairs and 574
replacements. MVS included 201 repairs and 185
replacements. The centers performed 92 to 365 procedures.
The patient characteristics are listed in Table 1 according to
the main outcome. Compared with the survivors, those who
died (11 patients after AVS and 14 after MVS) more
frequently had preoperative renal failure requiring
dialysis, previous cardiac surgery, active endocarditis,
critical preoperative state, diabetes requiring insulin,
advanced New York Heart Association class, poor left ven-
tricular ejection fraction, severe pulmonary hypertension,
nonelective operations, and longer bypass and crossclampgery c November 2014
TABLE 1. Baseline characteristics and univariate predictors of in-hospital mortality
Variable All (n ¼ 965) Survivors (n ¼ 940) Nonsurvivors (n ¼ 25) OR* (95% CI) P value
Age (y) 67  12 67  12 70  9 1.02 (0.99-1.06) .197
Female gender 45.5 45.5 44.0 0.94 (0.42-2.09) .879
Renal impairment
Creatinine clearance 50-85 mL/min 47.6 47.6 48.0 1.80 (0.63-5.17) .272
Creatinine clearance<50 mL/min 16.0 15.7 24.0 2.72 (0.82-9.07) .102
Dialysis 1.1 1.0 8.0 14.93 (2.55-87.53) .003
Extracardiac arteriopathy 6.0 6.0 8.0 1.37 (0.32-5.97) .673
Neurologic dysfunction 3.7 3.6 8.0 2.32 (0.52-10.23) .267
Previous cardiac surgery 9.8 9.1 36.0 5.59 (2.40-13.02) <.001
Bronchodilators or steroids for lung disease 5.2 5.1 8.0 1.62 (0.37-7.06) .523
Active endocarditis 4.2 3.5 32.0 12.93 (5.21-32.11) <.001
Critical preoperative state 0.7 0.5 8.0 16.26 (3.00-88.23) .001
Diabetes on insulin 5.8 5.5 16.0 3.25 (1.08-9.82) .036
NYHA class III-IV 55.5 54.7 88.0 6.08 (1.81-20.45) .004
Left ventricular ejection fraction
31%-50% 25.3 25.1 32.0 1.94 (0.78-4.80) .153
30% 2.4 1.9 20.0 15.88 (5.06-49.82) <.001
Recent myocardial infarction within 90 d 1.6 1.5 4.0 2.76 (0.35-21.82) .337
Systolic pulmonary artery pressure
31-55 mm Hg 25.8 25.9 24.0 1.19 (0.45-3.16) .729
>55 mm Hg 8.0 7.6 24.0 4.07 (1.50-11.04) .006
Nonelective operation 3.6 3.0 28.0 12.67 (4.9-32.77) <.001
Operative details
Bypass time (min) 100  40 99  38 146  72 1.19 (1.11-1.26) <.001
Crossclamp time (min) 74  34 74  29 89  34 1.13 (1.02-1.26) .018
Cardioplegic solution
Blood 91.9 92.0 87.0 1.00
Crystalloid 8.1 8.0 13.0 1.72 (0.50-5.93) .388
Temperature of cardioplegic solution
Cold 69.0 69.3 56.5 1.00
Warm 31.0 30.7 43.5 1.73 (0.75-4.00) .197
Delivery of cardioplegic solution
Antegrade 90.0 90.1 87.5 1.00
Retrograde 1.1 1.1 0.0 —
Both antegrade and retrograde 8.9 8.8 12.5 1.48 (0.44-5.09) .527
Data presented as mean  standard deviation or percentages. OR, Odds ratio; CI, confidence interval; NYHA, New York Heart Association. *OR per 10-unit increase in age,
bypass time, and crossclamp time.
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Mtimes. The different types of cardioplegic solutions used for
myocardial protection had no influence on survival.
Figure 1 shows the percentile of cTnI peak values
according to valve surgery type and in-hospital mortality
after AVS and MVS. The percentile ranked cTnI peak
values were greater in the MVS group than in the AVS
group and in nonsurvivors than in survivors in both surgery
groups. On multivariate regression analysis, the operative
variables listed in Table 1 were not associated with the
percentile ranked cTnI peak value, with the exception of
the bypass duration and MVS, which showed a positive
significant regression coefficient (both P<.001). The use
of a cardioplegic solution, temperature of the cardioplegic
solution, and delivery of the cardioplegic solution did not
influence cTnI release (P ¼ .26, P ¼ .17, and P ¼ .32,
respectively). The accuracy of the postoperative cTnI level
to discriminate between those patients who died and thoseThe Journal of Thoracic and Carwho survived, as quantified by the area under the receiver
operating characteristics curve, was 0.717 (95% CI,
0.545-0.888) for AVS and 0.708 (95% CI, 0.534-0.881)
for MVS. Figure E1 displays the receiver operating
characteristic curve of the percentile ranked cTnI peak
values for in-hospital mortality stratified by the surgery
type. The 60th percentile of the cTnI level in the AVS group
had 64% sensitivity and 72% specificity, with the greatest
sum of sensitivity and specificity. The cTnI values of the
60th percentile ranged within each clinic from 4.48 to
8.6 ng/mL. After MVS, the 91st percentile of cTnI
had 57% sensitivity and 86% specificity to distinguish
nonsurvivors and survivors. The 91st percentile of cTnI
ranged within each clinic from 12.27 to 38.90 ng/mL. The
presence of a cTnI percentile greater than the 60th percen-
tile in AVS and the 91st in the MVS group was significantly
associated on univariate analysis for hospital mortalitydiovascular Surgery c Volume 148, Number 5 2375
FIGURE 1. Median with interquartile range of percentile ranked cardiac
troponin I peak values stratified by (A) valve surgery and hospital mortality
in (B) aortic and (C) mitral valve surgery.
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M(OR, 5.18; 95% CI, 2.29-11.70; P< .001, for the entire
sample; OR, 4.58; 95% CI, 1.32-15.87; P ¼ .015, for the
AVS group; and OR, 7.85; 95% CI, 2.62-23.52; P<.001
for the MVS group).
The multivariate analysis results for hospital mortality
are listed in Table 2. Of the univariate predictors, only active2376 The Journal of Thoracic and Cardiovascular Surendocarditis, advanced New York Heart Association class,
poor left ventricular ejection fraction, and bypass duration
remained associated with in-hospital mortality. These
variables were considered for the reference predictive
model. When the cTnI peak percentile greater than the
60th in the AVS group and the 91st in the MVS group
was added to the reference model, the biomarker remained
significantly associated with mortality. Compared with the
reference model, the addition of cTnI resulted in significant
improvement in the goodness-of-fit (likelihood ratio, c2,
69.9 vs 76.7, with P ¼ .009 at the likelihood ratio test;
Nagelkerke R2 ¼ 0.327 vs 0.358; Akaike information
criterion, 172.2 vs 167.3), in discrimination (c-index,
0.832 vs 0.838), and reclassification (net reclassification
improvement, 0.751; P < .001; and integrated discri-
mination improvement, 0.048; P ¼ .002). The model
incorporating cTnI had significant effects compared with
reclassification. The net reclassification improvement
indicated that 75.1% of patients were better classified
when the cTnI level was included. Also, the significant
value of integrated discrimination improvement showed
that the addition of cTnI to the reference model led to
significant improvement in the ability to stratify the risk
of hospital mortality.
Postoperative Complications
The patients with a greater cTnI peak value in the entire
sample and, specifically, after MVS had significantly
greater rates of creatinine clearance reduction, postopera-
tive dialysis, reopening for complications and bleeding,
reintubation, insertion of a permanent pacemaker, sepsis,
intra-aortic balloon pump use, and hospital mortality
(Table 3). In AVS, a high cTnI peak value was associated
with creatinine clearance reduction, postoperative dialysis,
reopening for complications, sepsis, and hospital mortality.
Follow-up
For the 593 residents in Puglia, the link between patients
in the registry and the regional Health Information System
with the vital status updated after hospital discharge, was
obtained. Five patients died after discharge within 3 months
postoperatively. Troponin I values greater than the cutoff
value showed a significant effect compared with mid-term
mortality on univariate (hazard ratio, 4.58; 95% CI,
2.19-9.59; P< .001) and multivariate (hazard ratio, 3.38;
95% CI, 1.44-7.93; P ¼ .005) analysis, correcting for
variables in the reference model. Figure 2 shows the
cumulative mortality in the AVS and MVS subgroups
according to the postoperative cTnI peak values.
DISCUSSION
In the present study, we assessed whether adding the
postoperative cTnI level to the clinical variables resulted
in improved risk reclassification of the patients who hadgery c November 2014
TABLE 2. Multivariate logistic regression analysis for in-hospital mortality
Variable OR (95% CI) P value
Reference model Reference model plus cTnI
OR (95% CI) P value OR (95% CI) P value
Renal impairment requiring dialysis 2.37 (0.32-17.72) .401
Previous cardiac surgery 1.64 (0.50-5.41) .416
Active endocarditis 8.24 (2.29-29.6) .001 16.22 (5.68-46.31) <.001 15.12 (5.08-45.01) <.001
Critical preoperative state 1.44 (0.23-9.19) .700
Diabetes requiring insulin 2.29 (0.60-8.72) .225
NYHA class III-IV 3.83 (1.03-14.25) .045 4.56 (1.29-16.13) .019 5.42 (1.49-19.72) .010
Left ventricular ejection fraction  30% 17.98 (4.52-71.43) <.001 24.51 (6.89-87.18) <.001 26.59 (7.14-99.04) <.001
Systolic pulmonary artery pressure>55 mm Hg 1.74 (0.53-5.75) .363
Nonelective operation 2.20 (0.47-10.25) .314
Bypass time (min)* 1.18 (1.09-1.28) <.001 1.20 (1.11-1.29) <.001 1.14 (1.06-1.24) .001
High cTnI peak — — — — 3.88 (1.41-10.69) .009
High cTnI peak refers to values greater than the 60th in the AVS and 91st in the MVS group. OR, Odds ratio; NYHA, New York Heart Association; cTnI, cardiac troponin I.
*OR per 10-unit increase in bypass time.
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Mundergone AVS or MVS. The major finding of the present
study was that the postoperative cTnI level was significantly
associated with the in-hospital and mid-term mortality, with
significant improvement in the risk reclassification
measures in both AVS and MVS.
To date, far few smaller studies have evaluated
this aspect. Adabag and colleagues,5 in a retrospective,
single-center study, evaluated 696 CABG patients and 490
valve patients and demonstrated that greater cTnI elevation
after surgery was associated with increased mortality and a
greater incidence of myocardial infarction.5 The analysis of
the 490 valve patients was performed combining AVS and
MVS, and no information regarding survival after hospital
discharge was available. Monaco and colleagues6 reported
on about 185 patients undergoing MVS; however, owing
to the limited population, they could only evaluate the
predictors of cTnI release after surgery, without establish-
ing a significant effect on the patients’ prognosis.
By including a large number of patients from 5 different
centers and removing the differences that might exist
among the different assays using percentile ranking, the
present study investigated the effects of cTnI on mortality
after isolated AVS and MVS in patients without coronary
artery disease. We have shown that in valve surgery,
myocardial damage is a strong determinant of the postoper-
ative outcome, emphasizing the importance of myocardial
protection in this type of surgery. In MVS, the cTnI values
will be greater than those in AVS, probably reflecting the
need for left atrial muscle incision, vigorous retraction to
expose the valve, and the implantation of a prosthesis
directly into the muscular part of the mitral annulus when
the valve is replaced. It is, therefore, important to determine
the different cutoff for each type of surgery. A cTnI value of
15 ng/mL at 12 hours could be a relatively normal finding
after mitral valve replacement surgery but could be a
worrisome finding after aortic valve replacement. Future
studies are needed to clarify the influence of the initialThe Journal of Thoracic and Caraortic and mitral valve pathologic features (stenosis vs
insufficiency) on postoperative myocardial damage.
The incidence of postoperative complications was
enhanced in patients with cTnI levels greater than the
cutoff. After both AVS and MVS, acute kidney injury
and the need for permanent pacemaker insertion was
significantly influenced by myocardial damage.
Considering that perioperative myocardial infarction can
lead to increased mortality and morbidity after hospital
discharge, we extended the follow-up period to the first 3
months after surgery and found a significant negative effect
for greater cTnI release in the mid-term.
In our study, cTnI determinations were obtained using
different assays with different upper reference limits for
the 5 participating centers. The cTnI measurements could
not be directly compared among the different assays owing
to differences in the lower detection limits, upper reference
limits, diagnostic cutpoints, assay imprecision with difficult
standardization, and harmonization.9 Normalization is
required when the data have different measurement units
or in the case of absolute determinations not comparable
among manufacturers. The measures must be transformed
to a common scale before being combined. Some methods
of rescaling include (1) dividing each measure by its
standard deviation, (2) dividing each measure by its range,
(3) assigning a score according to a certain comparable
threshold, and (4) assigning a score according to the group’s
percentile ranking. The first 2 methods can be influenced by
extreme values or outliers and the third requires that the
commonly used 99th percentile concentrations should be
comparable among manufacturers. Ranking is the simplest
normalization technique and will not be affected by outliers.
To overcome this issue and to facilitate comparisons, the
cTnI peak values were transformed into percentile ranks
for each patient within each center; then, the ranked data
of the centers were combined for the global analysis. It is
important to note that we also performed the analysis withdiovascular Surgery c Volume 148, Number 5 2377
TABLE 3. Postoperative complication stratified by troponin I peak
value
Variable Overall
cTnI peak P
valueLow High
Entire sample (n) 965 739 226
Creatinine clearance reduction>50% 5.9 3.3 14.7 <.001
Dialysis 2.7 1.5 6.8 <.001
Atrial fibrillation 30.9 30.9 31.0 .973
Reopening for complications 0.7 0.1 2.7 <.001
Reopening for bleeding 6.0 5.0 9.3 .018
Reintubation 3.6 2.7 6.6 .006
Permanent pacemaker insertion 3.0 2.3 5.3 .020
Wound infection 0.3 0.4 0.0 .337
Sepsis 1.2 0.5 3.5 <.001
Stroke 0.6 0.5 0.9 .565
TIA 0.3 0.1 0.9 .076
Confusion or delirium 1.2 1.1 1.8 .414
Overall stay>30 d 2.1 1.8 3.1 .217
Intra-aortic balloon pump use 1.1 0.7 2.7 .024
Hospital mortality 2.6 1.4 6.6 <.001
AVS (n) 579 415 164
Creatinine clearance reduction>50% 7.0 4.6 13.2 <.001
Dialysis 2.6 1.7 5.0 .026
Atrial fibrillation 33.9 34.2 32.9 .768
Reopening for complications 0.7 0.0 2.4 .001
Reopening for bleeding 6.2 5.3 8.5 .146
Reintubation 2.9 2.4 4.3 .233
Permanent pacemaker insertion 2.6 1.9 4.3 .110
Wound infection 0.3 0.5 0.0 .373
Sepsis 1.0 0.5 2.4 .036
Stroke 0.5 0.2 1.2 .139
TIA 0.2 0.0 0.6 .111
Confusion or delirium 1.0 1.0 1.2 .784
Overall stay>30 d 2.4 1.9 3.7 .222
Intra-aortic balloon pump use 1.0 0.7 1.8 .359
Hospital mortality 1.9 1.0 4.3 .009
MVS (n) 386 324 62
Creatinine clearance reduction>50% 4.2 1.6 18.6 <.001
Dialysis 2.9 1.2 11.9 <.001
Atrial fibrillation 26.4 26.5 25.8 .904
Reopening for complications 0.8 0.3 3.2 .017
Reopening for bleeding 5.7 4.6 11.3 .038
Reintubation 4.7 3.1 12.9 .001
Permanent pacemaker insertion 3.6 2.8 8.1 .041
Wound infection 0.3 0.3 0.0 .661
Sepsis 1.6 0.6 6.5 .001
Stroke 0.8 0.9 0.0 .447
TIA 0.5 0.3 1.6 .190
Confusion or delirium 1.6 1.2 3.2 .246
Overall stay>30 d 1.6 1.5 1.6 .968
Intra-aortic balloon pump use 1.3 0.6 4.8 .031
Hospital mortality 3.6 1.9 12.9 <.001
Data presented as n or%. High cTnI peak refers to values greater than the 60th in AVS
and 91st in MVS. cTnI, Cardiac troponin I; TIA, transient ischemic attack; AVS, aortic
valve surgery; MVS, mitral valve surgery.
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Mrow cTnI values (data not shown), with results similar to
those obtained with percentile rank values. Therefore, for2378 The Journal of Thoracic and Cardiovascular Sureach cardiac procedure, according to the cTnI assays
adopted, a cutoff value for MVS and AVS able to predict
the risk of adverse outcome after surgery, should be
determined.
What is the clinical utility of measuring myocardial
damage biomarkers after surgery? In many postoperative
intensive care units, they are not routinely evaluated
because they are considered less essential than other clinical
parameters. In contrast, we believe it is of paramount
importance to perform a routine assessment of the
postoperative myocardial damage biomarkers. A simple
and inexpensive test can have critical prognostic power
that can be used to change routine therapy, enhancing
cardiovascular management with the possibility of reducing
the rate of adverse events. It has recently been shown that
even modest postoperative cTnI release will be associated
with new areas of myocardial infarction as assessed using
cardiac magnetic resonance imaging with late gadolinium
enhancement15; therefore, the importance of assessing the
efficacy of myocardial protection techniques and solutions
used for each operation cannot be denied. The determinants
of myocardial injury have been assessed for CABG16 but
not comprehensively for valve operations. In our study,
we did not examine the determinants of cTnI release after
surgery because of limited space; however, several triggers
not easily recordable in any registry should be considered,
including muscle incision and retraction, iatrogenic
coronary lesion, inadequate delivery of cardioplegia in
the case of aortic insufficiency or because of retraction of
the heart during administration, type of cardioplegia
used, and route of cardioplegia delivery.17-19 Increased
postoperative cTnI values could help the identification of
specific treatment in the intensive care unit (ie, early
angiography, intra-aortic balloon pump support) or might
indicate a need for revision of myocardial protection
strategies.
The present study had some limitations. Different assays
for cTnI evaluation were adopted in the different hospitals,
although a single, high-sensitivity assay would have been
preferable. However, we overcame this limitation by
percentile ranking. The accuracy of the cTnI peak
evaluation could have been influenced by the timing of
postoperative blood samples collected at intensive care
unit acceptance and serially thereafter every day of the
intensive care unit stay. Also, the mid-term follow-up data
were not complete, being limited to residents of the Puglia
region. The treating physicians were not unaware of the
cTnI results; therefore, we could not exclude the bias that
might have resulted from this knowledge.
The principle strength of our report was that the cTnI
values and clinical data were prospectively collected in a
institutional registry, with a link to an administrative
database to gather the midterm vital status. For the first
time, a specific assessment of the prognostic implicationsgery c November 2014
FIGURE 2. Cumulative mortality in (A) aortic and (B) mitral valve surgery according to postoperative troponin I peak value. A high troponin I peak refers
to values greater than the 60th in aortic and 91st percentile after mitral valve surgery.
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Mof myocardial injury after AVS and MVS has been reported
in a large sample size showing that cTnI is a powerful
predictor of mortality and morbidity and could be added
to validated preoperative and intraoperative risk factors.
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FIGUREE1. Receiver operating characteristic curve of percentile ranked
cardiac troponin I peak values for in-hospital mortality stratified by surgery
type (aortic valve and mitral valve surgery).
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